Back to search

Spain· ES:07398013

OPTIMARK 500 MICROMOL/ml SOLUCION INYECTABLE EN JERINGA PRECARGADA

A medicinal product containing gadoversetamida, registered in Spain by Mallinckrodt Deutschland Gmbh.

Checked against AEMPS CIMA (Spain) on

Informational only — not a medical device.

SOURCE REGISTER · ESAEMPS CIMA (Spain)normalisedOPTIMARK 500 MICROMOL/ml SOLUCION INY…ATC—REGISTER NO.ES:07398013PACKS LISTED0CHECKEDSeptember 12, 2026

The record

At a glance

AEMPS CIMA (Spain)
Active substance
gadoversetamida
Manufacturer
Mallinckrodt Deutschland Gmbh
Country
Spain (ES)
ATC code
—
Reimbursed
Not published by this register
Source register
AEMPS CIMA (Spain)
Last checked
September 12, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Gadoversetamida in 2 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All gadoversetamida products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ce065a5b-31db-4ef8-9049-73da58f26e78
GET /v1/drugs/ce065a5b-31db-4ef8-9049-73da58f26e78?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cpresc": "Uso Hospitalario Y Centros De Diagnóstico Autorizados",
  "estado": "{\"aut\":1197327600000,\"rev\":1738323614000}",
  "nregistro": "07398013",
  "substance": "gadoversetamida"
}

See everything about gadoversetamida.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.